Key stakeholders, rising stars and top sponsors in influenza research

New novel leaps forward has made it possible to develop drugs that can surpress replication of the flu virus within 24 hours. Many groups are now looking to develop universal flu vaccines that can hold off a variety of flu strains for multiple seasons. This week, we outline the key stakeholder in influenza research.

Read more

Key stakeholders, rising stars and top targets in Gene therapy for haemophilia

Gene therapy has long been the Holy Grail for treatment of haemophilia. This week we take a look at the top researchers, rising stars and institutions in this space.

Read more

Leading stakeholders within the emerging field of Microbiome-CNS research

The microbiome in the human intestine may have an impact on the functions of the central nervous system (CNS) and related disorders. A better understanding of this interplay could lead to new preventive and curative treatments, based on the modulation of intestinal microbiome. In this weeks issue we take a look at the top experts, institutions and main indications in the space.

Read more

Doubling the number of Investigators & expanding mapping capabilities!

In our quest to accelerate and improve your stakeholder mapping and engagement efforts we are today doubling the number of investigators and introducing new powerful mapping capabilities to the platform! Using a sophisticated activity linking approach, we have broadened the definition of an investigator to include a new type of investigator role – trial results author.

Read more

Key stakeholders, rising stars and top targets within CAR-T

For many, CAR-T it is considered one of the most promising cancer treatments. In this weeks ‘through the lens’ we take a look at the most prominent established opinion leaders, rising stars and top targets in the space.

Read more

Genome editing: Key Stakeholders within TALEN

We follow-up our previous post on CRISPR with an analysis of the stakeholder landscape within the competing/complementary genome editing technology TALEN.

Read more